Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2018

08.03.2018 | Epidemiology

Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab

verfasst von: P. S. Blanchette, D. N. Desautels, G. R. Pond, J. M. S. Bartlett, S. Nofech-Mozes, M. J. Yaffe, K. I. Pritchard

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We have limited capability to predict survival among patients treated for metastatic HER2-positive breast cancer. Further research is warranted to identify significant prognostic and predictive factors.

Methods

We identified all HER2-positive metastatic breast cancer patients receiving trastuzumab at the Sunnybrook Odette Cancer Centre (SOCC) from 1999 to 2013 through the Cancer Care Ontario (CCO) Registry (n = 256) and selected patients with available pathology reports (n = 154). A retrospective review was completed documenting clinical, pathologic, and laboratory characteristics at the time of first trastuzumab therapy and survival outcomes. Cox proportional hazards regression models were used to identify prognostic factors for overall survival (OS) (primary endpoint) and failure-free survival (FFS), adjusted for the known prognostic factors of the presence of CNS metastases and the presence of ≥ 2 distant metastatic sites.

Results

A multivariable model identified older age [hazard ratio (HR) 1.18/decade, 95% confidence interval (CI) 1.02–1.37)], increased platelet-to-lymphocyte ratio (PLR) (HR 1.75/log-unit, 95% CI 1.25–2.46), increased serum alkaline phosphatase (ALP) (HR 1.87/log-unit, 95% CI 1.41–2.49), and ER positivity (HR 0.63, 95% CI 0.42–0.96) as significant prognostic factors for OS after adjusting for the presence of CNS metastasis (HR 3.19, 95% CI 1.59–6.38) and the presence of ≥ 2 distant metastatic sites (HR 2.10, 95% CI 1.19–3.70). PLR (HR 1.54/log-unit, 95% CI 1.12–2.12) was the only prognostic factor associated with FFS after adjusting for CNS and ≥ 2 distant metastatic sites.

Conclusion

Older age, increased PLR, and ALP were identified as poor prognostic factors and ER positivity as a favorable prognostic factor for OS after adjusting for the presence of CNS metastasis and the presence of number of ≥ 2 distant metastatic sites. Increased PLR was a poor prognostic factor for both OS and FFS, and warrants further investigation into its prognostic ability amongst patients with HER2-positive metastatic breast cancer.
Literatur
1.
Zurück zum Zitat Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792CrossRefPubMed Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792CrossRefPubMed
3.
Zurück zum Zitat Balduzzi S et al (2014) Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 6:CD006242 Balduzzi S et al (2014) Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 6:CD006242
6.
Zurück zum Zitat Wolff AC et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013CrossRefPubMed Wolff AC et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013CrossRefPubMed
7.
Zurück zum Zitat Yardley DA et al (2014) Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer 110(11):2756–2764CrossRefPubMedPubMedCentral Yardley DA et al (2014) Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer 110(11):2756–2764CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Olson EM et al (2013) Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 22(4):525–531CrossRefPubMedPubMedCentral Olson EM et al (2013) Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 22(4):525–531CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22(17):3608–3617CrossRefPubMed Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22(17):3608–3617CrossRefPubMed
11.
Zurück zum Zitat Vaz-Luis I et al (2013) Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer 13(4):254–263CrossRefPubMedPubMedCentral Vaz-Luis I et al (2013) Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer 13(4):254–263CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Templeton AJ et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124CrossRefPubMed Templeton AJ et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124CrossRefPubMed
13.
Zurück zum Zitat Templeton AJ et al (2014) Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 23(7):1204–1212CrossRef Templeton AJ et al (2014) Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 23(7):1204–1212CrossRef
14.
Zurück zum Zitat Ethier JL et al (2017) Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 19(1):2CrossRefPubMedPubMedCentral Ethier JL et al (2017) Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 19(1):2CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Zhang M et al (2017) High platelet-to-lymphocyte ratio predicts poor prognosis and clinicopathological characteristics in patients with breast cancer: a meta-analysis. Biomed Res Int 2017:9503025PubMedPubMedCentral Zhang M et al (2017) High platelet-to-lymphocyte ratio predicts poor prognosis and clinicopathological characteristics in patients with breast cancer: a meta-analysis. Biomed Res Int 2017:9503025PubMedPubMedCentral
16.
Zurück zum Zitat Koh YW et al (2014) Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. Tumour Biol 35(10):9823–9830CrossRefPubMed Koh YW et al (2014) Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. Tumour Biol 35(10):9823–9830CrossRefPubMed
17.
Zurück zum Zitat Brufsky A et al (2005) Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 6(3):247–252CrossRefPubMed Brufsky A et al (2005) Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 6(3):247–252CrossRefPubMed
18.
Zurück zum Zitat Kaufman PA et al (2012) Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat 135(3):875–883CrossRefPubMedPubMedCentral Kaufman PA et al (2012) Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat 135(3):875–883CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Partridge AH et al (2013) Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 31(21):2692–2698CrossRefPubMed Partridge AH et al (2013) Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 31(21):2692–2698CrossRefPubMed
20.
Zurück zum Zitat Anders CK et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26(20):3324–3330CrossRefPubMed Anders CK et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26(20):3324–3330CrossRefPubMed
21.
Zurück zum Zitat Tripathy D et al (2014) The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer 14:307CrossRefPubMedPubMedCentral Tripathy D et al (2014) The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer 14:307CrossRefPubMedPubMedCentral
Metadaten
Titel
Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
verfasst von
P. S. Blanchette
D. N. Desautels
G. R. Pond
J. M. S. Bartlett
S. Nofech-Mozes
M. J. Yaffe
K. I. Pritchard
Publikationsdatum
08.03.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4734-x

Weitere Artikel der Ausgabe 1/2018

Breast Cancer Research and Treatment 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.